

Clinical Trials of Parkinson's Disease Drug Therapies Trial Change in Status* Dashboard: Q4 2022

*Registered, Started or Finished Recruiting, Completed
posted on ClinicalTrials.gov between Oct. 1, 2022 and Dec. 31, 2022

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Status	New Status
NCT03329508	P2B001	Pharma Two B	Rasagiline/ pramiprexole combination	Phase 3	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	525	Unknown status	Active, not recruiting
NCT03790670	Leukine (sargramostim)	Nebraska University	Recombinant GM- CSF	Phase 1	Biomarker Assessments of Leukine During Treatment of Parkinson's Disease	7	Recruiting	Active, not recruiting
NCT04148391	NYX-458	Aptinyx	NMDA receptor modulator	Phase 2	NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)	99	Recruiting	Active, not recruiting
NCT04334317	TAK-071	Takeda	M1 positive allosteric modulator	Phase 2	A Study of TAK-071 in People With Parkinson Disease	64	Recruiting	Active, not recruiting
NCT04831281	ATH-1017	Athira Pharma	Enhances Hepatocyte Growth Factor activity	Phase 2	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	28	Recruiting	Active, not recruiting
NCT05083260	NE3107	Biovie	Reduces neuroinflamm ation and insulin resistance	Phase 1 Phase 2	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	40	Recruiting	Active, not recruiting
NCT02542696	APL-130277 (Kynmobi)	Sunovion (part of Sumitomo Dainippon)	Sublingual apomorphine	Phase 3	Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease	427	Active, not recruiting	Completed

NCT02549092	Duodopa	Abbvie	Intestinal LD/CD	Phase 3	A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)	89	Active, not recruiting	Completed
NCT02655315	Deferiprone	ApoPharma (SKY)	Iron chelator	Phase 2	Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease	372	Active, not recruiting	Completed
NCT02953665	Liraglutide	Novo Nordisk/CPT LCT/Van Andel/Cedars Sinai	GLP-1 agonist	Phase 2	Safety and Efficacy of Liraglutide in Parkinson's Disease	63	Active, not recruiting	Completed
NCT04435431	IRL 790 (mesdopetam)	Integrative research laboratories/Ipsen	Dopamine D3 receptor antagonist	Phase 2	A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia	156	Active, not recruiting	Completed
NCT05568498	Ecologic BARRIER 849 (Probiotic)	British Columbia University	Probiotic	Phase 2	Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease	60	Not in CT.GOV	Not yet recruiting
NCT05611372	Rasagiline	Generics available	Monoamine oxidase-B inhibitor	Phase 2 Phase 3	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	732	Not in CT.GOV	Not yet recruiting
NCT05634876	UB-312	Vaxxinity (was United Neuroscience)	"Endobody" to aSN	Phase 1 Phase 2	UB-312 in Patients With Synucleinopathies	8	Not in CT.GOV	Not yet recruiting
NCT05669170	Methylphenidate	Ralph H. Johnson VA Medical Center	Dopamine and noradrenaline reuptake inhibitor	Phase 2	Methylphenidate for Apathy in Veterans With Parkinson's Disease	60	Not in CT.GOV	Not yet recruiting
NCT03652870	Nortriptyline/Escitalopram	University College London	Antidepressants	Phase 3	Antidepressants Trial in Parkinson's Disease	408	Not yet recruiting	Recruiting
NCT05377281	Autologous Unconditioned Peripheral Nerve Tissue	University of Kentucky	Peripheral nerve tissue	Phase 1	Feasibility and Safety of autologous Unconditioned Peripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)	10	Not yet recruiting	Recruiting
NCT05576818	Synbiotic	Tanta University	Lactobacillus acidophilus and prebiotic fibers	Phase 3	Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease	66	Not in CT.GOV	Recruiting

NCT05603312	AAV-GAD	MeiraGTx	Gene therapy	Phase 1 Phase 2	A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants	12	Not in CT.GOV	Recruiting
NCT05603715	Pyridostigmine	University of Vermont	Cholinesterase inhibitor	Phase 2	Pyridostigmine for the Treatment of Constipation in Parkinson Disease	16	Not in CT.GOV	Recruiting
NCT05635409	STEM-PD	Lund University & University of Cambridge	Ventral midbrain dopaminergic progenitor (stem) cells	Phase 1	A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease	8	Not in CT.GOV	Recruiting
NCT05642442	Suvecaltamide	Jazz Pharmaceuticals	Selective modulator of T type calcium channels	Phase 2	A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease	160	Not in CT.GOV	Recruiting
NCT02339064	SPN-830 (apomorphine (SQ infusion))	Supernus/US Worldmeds	Apomorphine infusion	Phase 3	Infusion of Apomorphine: Long-term Safety Study	99	Active, not recruiting	Unknown status
NCT04810104	AZD0328	King's College London/Astra Zeneca	a7 nicotinic receptor agonist	Phase 2	Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug	0	Not yet recruiting	Withdrawn